Thursday, June 28, 2018 02:30 PM

WITH FOOD ALLERGIES ON THE RISE, BIOTECH AIMMUNE IS FOCUSING ON RAISING PATIENTS' TOLERANCE

If you think food allergies are getting more and more prevalent in the United States, you're probably right.

Surveys have shown a stark increase[1] in allergy-related incidents in recent years. Experts estimate[2] that up to 20 million people in the United States are affected by food allergies, some of which can manifest in very severe ways.

Between 4 and 6 percent of children and 4 percent of adults are afflicted. The prevalence has led to lawsuits over restaurants' liabilities[3] in food-allergy incidents and studies on the psychological toll[4] allergies can take on patients.

But with its newest drug, biotechnology company Aimmune Therapeutics[5] is trying to buck the trend.

"What were doing is taking a technique thats been around for a while called oral immunotherapy and were making it widely available," Stephen Dilly, the company's founding executive chairman and former CEO, told CNBC.

"The idea is ...

News source: CNBC

See also: Steven Enrich